CORMORANT PHARMACEUTICALS
Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Chรขteau and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver of malignant tumors, HuMax-IL8 was acquired from Genmab A/S and taken into development by Cormorant. HuMax-IL8, is a fully human monoclonal antibody
CORMORANT PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2010-01-01
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Total Employee:
1+
Status:
Active
Similar Organizations
Erimos Pharmaceuticals
Erimos Pharmaceuticals is a biopharmaceutical company
Learmont Pharmaceuticals
Learmont Pharmaceuticals is a pharmaceutical company.
Tzana Pharmaceuticals
Tzana Pharmaceuticals is a pharmaceutical company.
More informations about "Cormorant Pharmaceuticals"
Cormorant Pharmaceuticals - Crunchbase Company Profile
Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver โฆSee details»
BMS Buys Rare Disease Biotech for Up to $500M
Jul 11, 2016 Bristol-Myers Squibb (BMS) acquired Swedenโs Cormorant Pharmaceuticals, a biotech specializing in drugs for rare diseases, on July 5 in a deal that could be worth up to $500 million. The agreement gives BMS total โฆSee details»
Cormorant Pharmaceuticals - LinkedIn
Cormorant Pharmaceuticals is a recently founded biopharmaceutical company focusing on the development of therapeutics for the treatment of cancer and rare diseases. Cormorant Pharmaceuticals ...See details»
Bristol-Myers Squibb buys cancer, rare disease biotech Cormorant
Jul 5, 2016 The rights to the drug originally came from a deal Cormorant struck with Copenhagen-based Genmab back in 2012, who itself bought the drug from Medarex in 2007- โฆSee details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of โฆSee details»
Cormorant Pharmaceuticals - PitchBook
Cormorant Pharmaceuticals General Information Description. Provider of pharmaceutical services. The company primarily focuses on developing therapeutics and related services for cancer and other rare diseases.See details»
Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals
Jul 5, 2016 Bristol-Myers Squibb Company (NYSE: BMY ) and Cormorant Pharmaceuticals revealed Tuesday that the former has acquired privately held Cormorant Pharmaceuticals' all โฆSee details»
Bristol-Myers Squibb acquires Cormorant โฆ
Jul 5, 2016 Cormorant Pharmaceuticals is a private, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to โฆSee details»
BMS Buys Cormorant Pharmaceuticals for Up to $520M
Jul 6, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a Sweden-based developer of cancer and rare-disease therapies, for up to $520 million, in a deal โฆSee details»
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
Jul 5, 2016 About Cormorant Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the โฆSee details»
Cormorant Pharmaceuticals - Products, Competitors, Financials ...
It recently acquired Cormorant Pharmaceuticals in an all-stock transaction with the deal worth up to $520 million to boost and strengthen its immuno-oncology pipeline. With this acquisition, it โฆSee details»
Cormorant Pharmaceuticals Acquired by BMS for $520M
Jul 11, 2016 Cormorant Pharmaceuticals, developer of cancer and disease therapies, has been acquired by Bristol-Myers Squibb in a move to expand BMS pipelines. ... Cormorant acquired โฆSee details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska โฆSee details»
Cormorant Asset Management's Strategic Acquisition in Corbus ...
Sep 25, 2024 The trade not only increased Cormorant's holdings in Corbus Pharmaceuticals by 350,000 shares but also impacted the firm's portfolio by 0.4%, enhancing its position to a โฆSee details»
BMS Acquires Cormorant Pharmaceuticals for Up to $520M
Jul 5, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a developer of cancer and rare-disease therapies, for up to $520 million, in a deal designed to broaden the โฆSee details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on โฆSee details»
Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential
Jul 5, 2016 Bristol-Myers Squibb has bought Swedish firm Cormorant Pharmaceuticals in a potentially $520 million deal, adding an antibody program designed to boost the efficacy of โฆSee details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Bristol-Myers Squibb Companyand Cormorant Pharmaceuticals have announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a โฆSee details»
Bristol-Myers Squibb buys rare disease biotech Cormorant โฆ
Jul 6, 2016 Bristol-Myers Squibb is to buy Cormorant Pharmaceuticals in a deal which could be worth up to $520m. Under the deal, Bristol-Myers Squibb has acquired all of the outstanding โฆSee details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, StockholmSee details»